DOCSLIB.ORG

Anhang Glossar Englisch–Deutsch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anhang Glossar Englisch–Deutsch Anhang Glossar Englisch–Deutsch Abadie’s sign Abadie-Zeichen, Adenohypophysis Adenohypophyse Dalrymple-Zeichen Adenoma of the thyroid gland Abdominal adiposity Fettverteilung, Schilddrüsenadenom abdominale Adenosine monophosphates Abdominal adipose tissue Fettgewebe, Adenosinmonophosphate viszerales Adenylate cyclase Adenylcyclase A-β-lipoproteinemia (ABL) Adipogenesis Lipogenese A-β-Lipoproteinämie Adipolysis Lipolyse Abnormal lipid metabolism Adiponectin Adiponectin Fettstoffwechselstörungen Adiposity Fettsucht Abnormal lipoprotein metabolism Adiposogenital dystrophia Fröhlich, Fettstoffwechselstörungen Morbus Accelerated hyperthyreoidism Krise, Adipsia Adipsie; Durstverhaltensstö- hyperthyreote rungen Acetatederivatives Essigsäure-Derivate Adolescent goitre Adoleszentenstruma Achard-Thiers syndrome Adrenal adenoma Nebennierenrinde- Achard-Thiers-Syndrom nadenom; Nebennierenrindentumoren, Acid-base balance Säure-Basen- benigne Haushalt Adrenal carcinoma Nebennierenrin- Acid-maltase deficiency Glykogenose, denkarzinom Typ II Adrenal cortex Nebennierenrinde Acidosis Azidose Adrenal cortex autoantibody Acne Akne Nebennierenrinden-Antikörper Acquired adrenogenital syndrome Adrenal gland Nebenniere adrenogenitales Syndrom, erworbenes Adrenal insufficiency Nebennierenrin- Acquired hyperlipoproteinemia deninsuffizienz Hyperlipoproteinämie, sekundäre Adrenal mass Nebennierentumoren Acromegaly Akromegalie Adrenal medulla Nebennierenmark; Acromicria Akromikrie Paraganglion, suprarenales Acropachy Akropachie Adrenal tumor Nebennierenrindentu- Activin Aktivin moren; Nebennierentumoren Actual value Istwert Adrenalectomy Adrenalektomie Acute thyroiditis Thyreoiditis, akute; Adrenaline Adrenalin Thyreoiditis, suppurative Adrenarche Adrenarche Addison’s disease Addison, Morbus Adrenergic Adrenerg Addison-Schilder syndrome Adrenergic receptor Adrenozeptor Adrenoleukomyelopathien Adrenocortical Adrenokortikal 1222 Glossar Englisch–Deutsch Adrenocortical insufficiency Alprostadil Alprostadil Insuffizienz, adrenokortikale Aluminium osteopathy Aluminiumos- Adrenocortical nonresponsiveness teopathie ACTH-Unempfindlichkeit Amenorrhea Amenorrhoe Adrenocorticotropic hormone Amine precursor upake and adrenokortikotropes Hormon decarboxylation APUD-System Adrenogenital syndrome Amine precursor upake and androgenitales Syndrom decarboxylation cells APUD-Zellen Adrenoleukodystrophy Adrenoleuko- Amino acid metabolism dystrophie; Adrenoleukomyelopathien Aminosäurestoffwechsel Adrenoleukodystrophy adult Aminoacidopathy Aminoazidopathien Adrenoleukodystrophie, im Aminoaciduria Aminoacidurie Erwachsenenalter Aminoglutethimide Aminoglutethimid Adrenoleukomyelopathy Amiodarone Amiodaron Adrenoleukomyelopathien Amiodarone hypothyroidism Adrenomyeloneuropathy Amiodaron-Thyreopathie Adrenoleukomyelopathien Amiodarone thyrotoxicosis Adult-onset diabetes Diabetes mellitus, Amiodaron-Thyreopathie Typ 2 Amiodarone-induced thyroid dysfunc- Agalactia Agalaktie tion Amiodaron-Thyreopathie Agalactosis Agalaktie Anabole steroids anabole Steroide Agenesis Agenesie Anabolism Anabolismus Agnus castus fruit extract Anacidity Anazidität Mönchspfefferfruchtextrakt Andersen’s disease Glykogenose, Typ Akro-osteolysis Akroosteolyse IV Albright’s hereditary osteodystrophy Androgen depriviation Androgende- Pseudohypoparathyreoidismus privation Albuminuria Albuminurie Androgen excess Hyperandrogenämie Aldolase Aldolase Androgen insensitivity syndrome Aldosterone Aldosteron Feminisierung, testikuläre Aldosterone synthase deficiency Androgen receptor Androgenrezepto- Hypoaldosteronismus, primärer ren kongenitaler Androgen release Androgenausschüt- Aldosteronoma Aldosteronom tung Alendronate Alendronsäure Androgen resistance Androgenresis- Alfacalcidol; α-Calcidol α-Calcidol tenz Algomenorrhoea Dysmenorrhoe Androgen synthesis Androgensynthese Alkalaemia Alkaliämie Androgenization Androgenisierung Alkaptonuria Alkaptonurie Androgens Androgene Allopurinol Allopurinol Android (abdominal) obesity Alloxan Alloxan Adipositas, androider Typ Alopecia Alpoezie Androstan derivatives Androstan- Alpha cells Alpha-Zellen Derivate Alpha-endorphin alpha-Endorphin Androstandiol Androstandiol Alpha-lipoprotein; α-Lipoprotein Androstandiol glucuronide Lipoproteine, hoher Dichte Androstandiolglukuronid Alpha melanocyte stimulating hormone Androstanolone Androstanolon Alpha-MSH Androstendione Androstendion Glossar Englisch–Deutsch 1223 Androsterone Androsteron Anti-mullerian hormone Aneurine Thiamin Anti-Müller-Hormon Angiotensin converting enzyme (ACE) Antioestrogens Antiöstrogene Angiotensin-Konversionsenzym Antisense-mRNA techniques Angiotensin I Angiotensin I mRNA-anti-sense-Technik Angiotensin II Angiotensin II Antithyroglobulin antibodies Angiotensin III Angiotensin III Thyreoglobulin-Antikörper Angiotensinogen Angiotensinogen Antithyroid drug Thyreostatikum Anorchia Anorchie α1-antitrypsin-deficiency Anovulatory bleeding Blutung, α1-Antitrypsinmangel anovulatorische Anxiety disorder Angsterkrankung Anovulatory cycle Anovulation Apolipoproteins Apolipoproteine Antagonist Antagonist Apomorphine Apomorphin Anterior pituitary Adenohypophyse; Apparent mineralocorticoid excess Hypophysenvorderlappen Mineralokortikoidexzess, scheinbarer Anterior pituitary hormones Appetizers appetitstimulierende Mittel Hypophysenvorderlappenhormone Arachidonic acid Arachidonsäure Anterior pituitary lobe Adenohypo- Arcuate nucleus Nucleus arcuatus physe Argininaemia Argininämie Anti-androgens Antiandrogene Arginine Arginin Antidiabetic drugs Antidiabetika Arginin-vasopressin Argipressin Antidiabetic substances Antidiabetika Argipressin Argipressin Antidiabetic substances of plant origin Aromatase Aromatase Antidiabetika, pflanzliche Aromatase deficiency Aromataseman- Antidiuresis Antidiurese gel Antidiuretic hormone Antidiuretisches Aromatase inhibitors Aromatasehem- Hormon mer Antidiuretic hormone (ADH) Arteriosclerosis Arteriosklerose Vasopressin (AVP) Arthritis associated with Antidiuretic hormone-system endocrinopathies Arthritis bei ADH-System endokrinen Störungen Anti-dysmenorrhoica Antidysmenor- Ascorbic acid Vitamin C rhoika Atrial natriuretic hormone Atrio- Antiestrogens Antiöstrogene peptin Antigestagens Antigestagene Atrial natriuretic peptide Peptid, Anti-gonadotropins / gonadotropin atriales natriuretisches antagonists Antigonadotropine Atriopeptide Atriopeptin Antihormones Antihormone Atriopeptin Atriopeptin Antihyperuricemic agents Gichtmittel Atrophia Atrophie; Atrophie, Anti-infective agents Antiinfektiva, pathologische gynäkologische Atrophic thyroiditis Thyreoiditis, Antiinfectives Antiinfektiva, atrophische gynäkologische Atrophy Atrophie; Atrophie, Antilipemic Lipidsenker pathologische Anti-lipidamics Antilipidämika Atyreosis Schilddrüsenaplasie Antimicrosomal antibodies Autocrine secretion Sekretion, Thyreoidale mikrosomale Antikörper autokrine 1224 Glossar Englisch–Deutsch Autoimmune polyendocrine Benign pancreatic tumor syndrome (APS) Polyglanduläres Pankreastumoren, benigne Autoimmunsyndrom Benign thyroid tumors Schilddrüsen- Autoimmune polyendocrine syndrome tumoren, benigne type I (APS-I) Polyglanduläres Benzbromarone Benzbromaron Autoimmunsyndrom Typ I Beriberi Beriberi Autoimmune polyendocrinopathy- Beta carotene Betacaroten candidiasis-ectodermal dystrophy Beta-3-adrenergic-receptor (APECED) Polyglanduläres Beta-3-Rezeptor, adrenerger Autoimmunsyndrom Typ I Beta-3-adrenergic-receptor gene Autoimmune thyroiditis Thyreoiditis, Beta-3-Rezeptor-Gen, adrenerges autoimmune Beta-endorphin Beta-Endorphin Autointoxication Autointoxikation Beta-lipoprotein Lipoproteine, Autonomous adenoma of the thyroid niedriger Dichte Adenom, autonomes der Schilddrüse Betamethasone Betamethason Autonomous goiter Struma mit BGP Osteocalcin Autonomie b-HCG Beta-HCG Autonomy of the thyroid Struma mit Bicalutamide Bicalutamid Autonomie Biguanide Biguanide Autonomy of the thyroid gland Struma Bioassay Bioassay mit Autonomie Biocatalysators Biokatalysatoren Autoreceptor Autorezeptor Biogenic amines Amine, biogene Axillary temperature Axillartempera- Biotin Biotin tur Birth control pill Antibabypille Azotemia Azotämie Bisphosphonate Bisphosphonate Azoturia Azoturie Bleeding after the normal menstruation Postmenstruelle Blutung Bleeding due to organic cause Blutung, Bacterial thyroiditis Thyreoiditis, organisch bedingte suppurative Bleeding in the postmenopause Baroceptor Barosensorreflex Postmenopausenblutung Baroreceptor Barosensor; Blood glucose concentration BarosensorreflexBreast Blutzucker Bartter’s syndrome Bartter-Syndrom Blood pressure Blutdruck Basal body temperature B-lymphocytes B-Lymphozyten Aufwachtemperatur; Basaltemperatur Body mass index Gewicht-Längen- Basedow goiter Struma bei Morbus Indizes Basedow Bone development retardation Basic fibroblast growth factor Ossifikationsstörung, allgemeine Fibroblastenwachstumsfaktor, basischer Bone formation retardation Basophil pituitary adenoma Ossifikationsstörung, sekundäre Hypophysenadenom, basophiles Bone gamma-carboxylglutamic Basophilic pituitary adenoma acid-containing protein Osteocalcin Hypophysenadenom, basophiles Bone-Gla-Protein Osteocalcin Benign adrenal tumor Nebennieren- Bradykinin Bradykinin rindentumoren, benigne Brancher deficiency glycogenosis Benign nodule of the thyroid Glykogenose, Typ IV Schilddrüsenadenom Breast Brustdrüse; Milchdrüse Glossar Englisch–Deutsch 1225 Brittle bone disease Osteogenesis C-cell carcinoma of the thyroid imperfecta Schilddrüsenkarzinom, medulläres Brittle diabetes Brittle Diabetes C-cells C-Zellen Broca’s formula Broca-Formel Celecoxib
Load more

Recommended publications
  • Prescription Drug List
    Your 2017 Prescription Drug List Effective January 1, 2017 Oxford Connecticut Traditional Three-Tier Please read: This document contains information about commonly prescribed medications. This Prescription Drug List (PDL) is accurate as of August 1, 2016 and is subject to change after this date. The next anticipated update will be in January 2017. Your estimated coverage and copay/co-insurance may vary based on the benefit plan you choose and the effective date of the plan. For more information: Call us at the toll-free phone number on your health plan ID card. TTY users can dial 711. Si usted necesita ayuda en español llame al número de teléfono en su tarjeta de identificación, 1- 800-303-6719, 1-888-201-4746. Visit oxfordhealth.com, click on the Pharmacies & Prescriptions tab and then “Online Pharmacy” to log in to the OptumRx1 website and: • Locate a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. 1OptumRx is the administrator of your Oxford pharmacy benefit plan. Note: Diabetic supplies and prescription medications may be subject to different cost-share arrangements. Specialized non-standard infant formulas and nutritional supplements may be subject to prior authorization. Please see your Summary of Benefits and Coverage (SBC) for specifics. 1 Your Prescription Drug List This Prescription Drug List (PDL) outlines covered medications and organizes them into cost levels, also known as tiers. An important part of the PDL is giving you choices so you and your doctor can choose the best course of treatment for you. Go to oxfordhealth.com for drug information.
    [Show full text]
  • Aphrodisiac & Tonic Activity of Tribulus Leaf
    No. 57 January 2011 Aphrodisiac & Tonic Activity of Tribulus Leaf Key Points at a Glance Tribulus Leaf Constituents & Quality • consumed as a vegetable and used traditionally as a tonic • contains furostanol glycosides (which are steroidal • concentrated extract of Tribulus leaf (of Eastern European saponins), in particular, protodioscin origin and/or containing furostanol saponins, predominantly • protodioscin level may be critical for efficacy protodioscin) clinically demonstrated to: • fruit as well as plant grown in locations other than Eastern − improve sperm and semen parameters in men with Europe may contain furostanol saponins, but not necessarily infertility with sufficient protodioscin − improve libido in men • method of analysis determines the accuracy of furostanol − improve ovulation in some women with infertility saponin content − relieve menopausal symptoms • much clinical research published on Tribulus but often − possibly enhance the body’s natural production of sex undefined for plant part, saponin profile or content of hormones, especially when at low levels, but is unlikely protodioscin to increase beyond normal range • steroidal saponins may act by binding to vacant receptors in the hypothalamus Traditional Uses The high content of steroidal saponins is a characteristic feature of Tribulus terrestris . The composition of the There is little information available on the traditional use saponins correlates with the place of origin of the plant. of the leaf of Tribulus ( Tribulus terrestris ). In Ayurveda the The main constituent of Tribulus aerial parts (leaf and plant and fruit have been used to treat spermatorrhoea, stem) from Bulgaria is the furostanol glycoside gonorrhoea, impotence, uterine disorders after parturition, protodioscin. 10 cystitis, painful urination, kidney stones and gout.
    [Show full text]
  • BRS Pharmacology
    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 2018 Formulary Drug List
    2018 Formulary Drug List For Federal Employees Health Benefits Program Employees GlobalHealth, Inc. 701 NE 10th Street, Suite 300 Oklahoma City, OK 73104-5403 MFEHBDF18 Lists Updated 12/2017 www.GlobalHealth.com/fehb HELPFUL NUMBERS Plan Issuer: Medication Prior Authorizations: GlobalHealth, Inc. [email protected] PO Box 2393 918.878.7361 Oklahoma City, OK 73101-2393 Mail Claims to: GlobalHealth Customer Care, Language Magellan Rx Management, LLC Assistance, and Disease Management: PO Box 85042 [email protected] Richmond, VA 23261-5042 405.280.2989 (local) 1.877.280.2989 (toll-free) Mail Order Pharmacy: 711 (TTY) Magellan Rx Management, LLC Monday – Friday, 9 a.m. – 5 p.m. Central 1.800.424.1789 (toll-free) www.GlobalHealth.com/fehb 711 (TTY) P.O. Box 620968 Behavioral Health and Substance Use: Orlando, FL 32862 [email protected] 405.280.2989 (local) 24/7 Nurse Help Line: 1.877.280.2989 (toll-free) Information Line 711 (TTY) 1.877.280.2993 (toll-free) Monday – Friday, 9 a.m. – 5 p.m. Central www.GlobalHealth.com/fehb GlobalHealth Compliance Officer: 1.877.280.5852 (toll-free) Pharmacy Benefits Manager: 405.280.5852 Magellan Rx Management, LLC [email protected] Customer Service 1.800.424.1789 (toll-free) GlobalHealth Privacy Officer: 711 (TTY) 405.280.5524 [email protected] i IMPORTANT INFORMATION This formulary applies to Members who enrolled through the Federal Employees Health Benefits Program. Member Materials Your Member materials are three booklets. Each one has a different purpose. These documents are important legal documents. Keep them in a safe place. Booklet Purpose FEHB Brochure Tells you about your benefits.
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]
  • Electrochemical Behaviour and Quantitative Determination Of
    Int J Pharma Res Health Sci. 2017; 5 (6): 2014-18 DOI:10.21276/ijprhs.2017.06.22 Reddy et al CODEN (USA)-IJPRUR, e-ISSN: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Electrochemical Behaviour and Quantitative Determination of Clomifene in Pharmaceutical Formulations C Nageswara Reddy1,*, P Sandhya 3, P R Prasad 2, N Y Sreedhar 2 1Department of Chemistry, Govt. Degree & P.G. College, Puttur-517 583, A.P., India. 2Electroanalytical Lab, Department of Chemistry, Sri Venkateswara University, Tirupati-517 502, A.P, India. 3Department of Chemistry, Sri Padmavati Mahila Visvavidyalayam, Tirupati-517 502, A.P, India. ARTICLE INFO ABSTRACT Received: 11 Nov 2017 The electrochemical behaviour of clomifene was studied and determined in pharmaceutical Accepted: 18 Dec 2017 formulations. The drug of clomifene was electrochemically examined by cyclic and differential pulse voltammetry using a glassy carbon electrode (GCE). The obtained results showed that, the Britton Robinson buffer with pH 4.0 was the best medium for reduction of clomifene on the glassy carbon electrode at the peak potential -1.01 V. The range of linearity was found to be from 0.20 μg mL-1 to 60.0 μg mL-1 (R2 = 0.994) with limit of detection (LOD) 0.168 μg mL-1 and limit of quantification (LOQ) was 0.511 μg mL-1. Differential pulse voltammetric method was successfully applied for the electrochemical determination of clomifene in pharmaceutical formulations ______ Keywords: Clomifene, drug, voltammetry, pharmaceutical formulations. 1. INTRODUCTION An alkenyl group containing molecules play a vital role in drug chemistry.1 There are innumerable chemical reactions that involve or produce a carbon-carbon double bond group as an intermediate or as an end produce.1 Consequently the discovery of the first non-steroidal antiestrogen, several studies have been conducted to determine the mechanism of Corresponding author * action of this classes of compounds.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Hormone Replacement Therapy and Osteoporosis
    This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers— patients and clinicians, health system leaders, and policymakers—make more informed decisions and improve the quality of health care services. Systematic Evidence Review Number 12 Hormone Replacement Therapy and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0018 Task Order No. 2 Technical Support of the U.S. Preventive Services Task Force Prepared by: Oregon Health Sciences University Evidence-based Practice Center, Portland, Oregon Heidi D. Nelson, MD, MPH August 2002 Preface The Agency for Healthcare Research and Quality (AHRQ) sponsors the development of Systematic Evidence Reviews (SERs) through its Evidence-based Practice Program. With guidance from the third U.S. Preventive Services Task Force∗ (USPSTF) and input from Federal partners and primary care specialty societies, two Evidence-based Practice Centers—one at the Oregon Health Sciences University and the other at Research Triangle Institute-University of North Carolina—systematically review the evidence of the effectiveness of a wide range of clinical preventive services, including screening, counseling, immunizations, and chemoprevention, in the primary care setting.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]